Fluorescence method for on-site detection of acetamiprid based on nano magnetic beads
Through the fluorescence detection method based on nanomagnetic beads, the acetaminine-specific nucleic acid aptamide modified biotin is used to bind to streptavidin-modified magnetic beads, and the detection is combined with fluorescent quantum dot labeled cDNA, which solves the existing technology The harsh and high cost of detection equipment of Zhongdine acetaminine has achieved a field detection effect with high specificity and strong anti-interference ability.
Patent Information
- Application Number
- CN202411336363.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-09-25
AI Technical Summary
The existing acetamiprid detection methods have problems such as harsh equipment usage conditions, high cost, susceptible to environmental impacts and batch differences, which limit their application and promotion.
Using a fluorescence detection method based on nanomagnetic beads, the acetaminamid-specific nucleic acid aptamide modified biotin is combined with streptavidin-modified magnetic beads, and the cDNA is labeled with fluorescent quantum dots is used for detection, and the magnets are separated and performed. Fluorescence spectroscopy measurement enables rapid and specific detection of acetamiprid.
Acetamiprid detection has been achieved with strong anti-interference ability, simple analysis process, strong specificity and good stability, which reduces detection costs, improves operational convenience and sensitivity, and avoids false positive results.
Smart Images

Figure CN118937680A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of analytical chemistry and biotechnology, and particularly relates to a fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads. Background Art
[0002] Acetamiprid (ACE) is a neonicotinoid insecticide with a chemical formula of C 10 H 11 ClN4 is used to replace conventional highly toxic pesticides such as organophosphorus and organochlorine in agricultural products such as fruits and vegetables due to its advantages of high efficiency, broad spectrum, low toxicity and low cost. However, acetamiprid will accumulate in the body through the food chain for a long time, threatening human health and causing irreversible damage to the central nervous system. Therefore, it is necessary to develop an analytical method for rapid on-site detection of acetamiprid.
[0003] At present, the detection methods for pesticide residues in traditional Chinese medicines mainly include the following two categories. The first category is chromatography-mass spectrometry, such as liquid chromatography-tandem mass spectrometry (LC-MS), ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS), ultra-fast liquid chromatography-time-of-flight mass spectrometry (UHPLC-ToF-MS), etc. This type of method has high sensitivity and accuracy, but the equipment use conditions are harsh and require professional technicians to operate, so the application is limited by conditions. The second category is immunoassay, among which enzyme-linked immunosorbent assay (ELISA) is the most commonly used. This method has high sensitivity, strong specificity, and is easy to carry, but due to the presence of antibodies and biological enzymes HRP in its system composition, the cost is relatively high, and the biological enzymes are easily affected by environmental factors such as temperature. The preparation of antibodies is prone to batch differences, which to a certain extent has caused the actual application and promotion of ELISA to be limited.
[0004] In this method, nucleic acid aptamers are used as recognition elements, which have the advantages of strong specificity, low cost, high affinity, and easy chemical modification, and have been widely used in the field of rapid detection.
[0005] The nanomagnetic beads used in this method have the characteristics of good fluidity, small size, strong suction, good biocompatibility, etc. By modifying the surface of the magnetic beads with streptavidin, amino groups, etc., and using the binding principles of streptavidin-biotin, amino-carboxyl, etc., the magnetic beads can capture target molecules such as nucleic acids, proteins or peptides. More importantly, the nanomagnetic beads modified with aptamers can quickly capture the target and separate it from the original detection system under the action of the external magnetic field, thereby reducing the interference of other substances in the complex detection environment.
[0006] Quantum dots themselves have a certain fluorescence, and have the advantages of large specific surface area, high fluorescence quantum yield, high photochemical stability, etc. Quantum dots can be identified by naked eyes under a fluorescence microscope, and have been widely used in biosensing, in vitro and in vivo imaging, heavy metal ion detection in the environment, and food safety testing. Combining with magnetic beads and quantum dots to construct fluorescent aptamer sensors can effectively improve the sensor's specific recognition ability for targets, and can be used for the detection and analysis of acetamiprid. Summary of the invention
[0007] The purpose of the present invention is to provide a fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads in view of the defects of the prior art. The method has strong anti-interference ability, simple analysis process, strong specificity, good stability, and can be used for on-site rapid detection of acetamiprid.
[0008] To achieve the above object, the present invention adopts the following technical solution: A fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads: a biotin-modified acetamiprid-specific aptamer (Apt) probe is fixed on the surface of streptavidin-modified magnetic beads (MBs). When acetamiprid (ACE) is present, the aptamer and acetamiprid bind to each other to form a stable magnetic bead-aptamer-acetamiprid complex. Subsequently, cDNA labeled with fluorescent quantum dots (QD) is added, and the aptamer (Apt) that has bound to acetamiprid can no longer bind to the cDNA. At this time, a magnet is used to remove the magnetic beads (MBs), and the fluorescence spectrum of the supernatant is measured to detect different concentrations of acetamiprid.
[0009] A fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads comprises the following specific steps: (1) Preparation of fluorescent quantum dot-labeled cDNA complex: 50 μL of 100 nM cDNA modified with biotin and 50 μL of 100 nM QD solution modified with streptavidin were placed in a centrifuge tube and incubated at 25°C for 1 h to obtain a fluorescent quantum dot-labeled cDNA complex QD-cDNA; (2) Preparation of magnetic bead-aptamer complex: Wash the streptavidin-modified magnetic beads MBs three times with 200 μL of WB buffer at pH 7.5, and resuspend them in 100 μL of 10 mM PBST buffer at pH 7.4 to make the final concentration of the magnetic beads 150 μg / mL; then add 50 μL of 1 μM biotin-modified acetamiprid-specific aptamer Apt, vortex for 30 s, and incubate at 25°C for 1 h. At this time, the biotin modified on Apt combines with the streptavidin modified on MBs to form a magnetic bead-aptamer MBs-Apt complex. After magnetic separation and removal of the supernatant, add 200 μL of PBS-T buffer, repeat washing three times, remove excess Apt in the supernatant, and resuspend in 100 μL PBST buffer to prepare MBs-Apt solution; (3) Fluorescence detection of acetamiprid: 100 μL of the MBs-Apt solution prepared in step (2) and 20 μL of a certain concentration of acetamiprid solution diluted with pH 7.4 PBS buffer were placed in a centrifuge tube, vortexed for 10 s, and incubated at 30°C for 60 min. Subsequently, 50 μL of the QD-cDNA complex prepared in step (1) was added, vortexed to mix, and incubated at 25°C for 60 min. Subsequently, the MBs were separated from the supernatant using a magnet, and the supernatant was placed in a 96-well black ELISA plate. The fluorescence intensity of the supernatant was detected using a multifunctional ELISA reader.
[0010] The nucleotide sequence of the cDNA in the above step (1) is: 5'-Biotin-TCTTCATAATATGGTGTCAG-3'.
[0011] The nucleotide sequence of the acetamiprid aptamer Apt in the above step (2) is: 5'-Biotin-CTGACACCATATTATGAAGA-3'.
[0012] In the above method: The WB buffer (pH 7.5) formula is as follows: 1.2114 g of Tris was weighed and dissolved in ultrapure water, and then dilute HCl was added to adjust the pH to 7.5, and then 0.3722 g of EDTA and 0.117 g of NaCl were added, ultrasonicated for 30 s, and ultrapure water was added to make up to 1 L.
[0013] The PBS buffer solution (pH 7.4) is formulated as follows: 8.0000 g of NaCl, 0.2013 g of KCl, 3.5814 g of Na2HPO4 and 0.2722 g of KH2PO4 are weighed and added with ultrapure water to make up to 1 L.
[0014] The PBS-T buffer solution formula is: the above-mentioned pH 7.4 PBS buffer solution + 0.5 mL Tween-20.
[0015] The concentration of the acetamiprid solution in the above step (3) is 20-55 μg / mL.
[0016] The above-mentioned fluorescence method for detecting acetamiprid based on nanomagnetic beads is applied in the detection of acetamiprid.
[0017] The technical principle of the present invention is: The present invention fixes the acetamiprid-specific aptamer Apt probe modified with biotin on the surface of MBs modified with streptavidin. When acetamiprid ACE is present, Apt and acetamiprid bind to each other to form a stable MBs-Apt-ACE complex. Subsequently, cDNA labeled with fluorescent quantum dots QD is added, and Apt that has bound to acetamiprid can no longer bind to cDNA. At this time, a magnet is used to remove MBs, and fluorescence detection is performed on the supernatant. The higher the concentration of acetamiprid, the greater the fluorescence intensity of the supernatant, thereby achieving the detection of acetamiprid. The above principle diagram is shown in Figure 1 .
[0018] In this method, nucleic acid aptamers are used as recognition elements, which can not only ensure the specific recognition of acetamiprid during detection, but also reduce the detection cost. The introduced nanomagnetic beads have the characteristics of good fluidity, small size, strong adsorption, and good biocompatibility. Not only can they make the specific operation simpler and faster, but their large specific surface area can also amplify the signal to a certain extent and improve the sensitivity of the method. More importantly, its use greatly improves the anti-interference ability of the method. Nanomaterial quantum dots themselves have a certain fluorescence, and have the advantages of large specific surface area, high fluorescence quantum yield, and high photochemical stability, which can improve the stability and sensitivity of the method.
[0019] The advantages of the present invention are: 1. The present invention utilizes acetamiprid-specific aptamers as biological recognition elements, thereby ensuring the stability and selectivity of the detection method.
[0020] 2. The present invention introduces magnetic beads and quantum dots to construct fluorescent aptamer sensors, which can effectively improve the operational convenience, sensitivity and anti-interference ability of the method.
[0021] 3. The present invention achieves highly specific detection of acetamiprid, is easy to operate, has strong anti-interference ability, and is suitable for on-site detection of acetamiprid.
[0022] 4. This method is a “signal-on” detection method, which can avoid the “false positive” results of the “signal-off” method. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 Schematic diagram of the nanomagnetic bead-based fluorescent biosensing method for detecting acetamiprid.
[0024] Figure 2 The method of the present invention detects the fluorescence detection results of acetamiprid of different concentrations and establishes a standard working curve.
[0025] Figure 3 Specificity verification of the method of the present invention for detecting acetamiprid. DETAILED DESCRIPTION
[0026] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further explained below in combination with specific implementation methods. However, the following examples are merely examples of the present invention and do not represent the scope of protection of the rights limited by the present invention. The scope of protection of the present invention shall be subject to the claims.
[0027] Example 1 A fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads comprises the following specific steps: (1) Preparation of QD-cDNA complex: 50 μL of 100 nM cDNA modified with biotin and 50 μL of 100 nM QD solution modified with streptavidin were placed in a centrifuge tube and incubated at 25°C for 1 h to obtain the QD-cDNA complex; (2) Preparation of magnetic bead-aptamer complex: Wash the streptavidin-modified magnetic beads MBs three times with 200 μL of WB buffer at pH 7.5, and resuspend them in 100 μL of 10 mM PBST buffer at pH 7.4 to make the final concentration of the magnetic beads 150 μg / mL; then add 50 μL of 1 μM biotin-modified acetamiprid-specific aptamer Apt, vortex for 30 s, and incubate at 25°C for 1 h. At this time, the biotin modified on Apt combines with the streptavidin modified on MBs to form a magnetic bead-aptamer MBs-Apt complex. After magnetic separation and removal of the supernatant, add 200 μL of PBS-T buffer, repeat washing three times, remove excess Apt in the supernatant, and resuspend in 100 μL PBST buffer to prepare MBs-Apt solution; (3) Fluorescence detection of acetamiprid: 100 μL of the MBs-Apt solution prepared in step (2) and 20 μL of a certain concentration of acetamiprid solution diluted with pH 7.4 PBS buffer were placed in a centrifuge tube, vortexed for 10 s, incubated at 30°C for 60 min, and then 50 μL of the QD-cDNA complex prepared in step (1) was added, vortexed to mix, and incubated at 25°C for 60 min. MBs were then separated from the supernatant using a magnet, and the collected supernatant was placed in a 96-well black ELISA plate. The fluorescence intensity of the supernatant was detected using a multifunctional ELISA reader.
[0028] The nucleotide sequence of the cDNA in the above step (1) is: 5'-Biotin-TCTTCATAATATGGTGTCAG-3'.
[0029] The nucleotide sequence of the acetamiprid aptamer Apt in the above step (2) is: 5'-Biotin-CTGACACCATATTATGAAGA-3'.
[0030] In the above method: The WB buffer (pH 7.5) formula is as follows: 1.2114 g of Tris was weighed and dissolved in ultrapure water, and then dilute HCl was added to adjust the pH to 7.5, and then 0.3722 g of EDTA and 0.117 g of NaCl were added, ultrasonicated for 30 s, and ultrapure water was added to make up to 1 L.
[0031] The PBS buffer solution (pH 7.4) is formulated as follows: 8.0000 g of NaCl, 0.2013 g of KCl, 3.5814 g of Na2HPO4 and 0.2722 g of KH2PO4 are weighed and added with ultrapure water to make up to 1 L.
[0032] The PBS-T buffer solution formula is: the above-mentioned pH 7.4 PBS buffer solution + 0.5 mL Tween-20.
[0033] Example 2 The concentrations of the acetamiprid solution added in step (3) of Example 1 were set to 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL, and 55 μg / mL, respectively, and the remaining steps were the same as in Example 1. Fluorescence detection of acetamiprid at different concentrations was achieved. The detection results are shown in Figure 2 It can be seen that as the concentration of acetamiprid increases, the fluorescence intensity value F of the system also increases.
[0034] By analyzing the relationship between the fluorescence intensity F and the concentration of acetamiprid, a standard curve was established ( Figure 2), to achieve quantitative detection of acetamiprid. The detection limit (LOD) of this method was calculated by 3σ / S (where σ represents the standard deviation of the signal measured multiple times in the blank test solution, and S is the slope of the fitted linear equation), and the theoretical detection limit of this method was 0.90 μg / mL.
[0035] Example 3 Specificity Verification The acetamiprid solution in step (3) of Example 1 was replaced with 5 common pesticide residue solutions of atrazine, phoxim, thiamethoxam, chlorpyrifos, and imidacloprid, all with a concentration of 200 μg / mL, and the acetamiprid concentration was 20 μg / mL, to verify the specificity of the method of the present invention. The test results are shown in Figure 3 It can be seen that even if the concentration of the interfering pesticide residues is 10 times that of acetamiprid, their fluorescence intensity change values are still significantly lower than that of acetamiprid. The results show that the method established in this application has good specificity for acetamiprid detection.
[0036] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.
Claims
1. A fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads, characterized in that: The biotin-modified acetamiprid-specific nucleic acid aptamer probe is fixed on the surface of streptavidin-modified magnetic beads. When the target acetamiprid is present, the nucleic acid aptamer specifically binds to acetamiprid to form a stable magnetic bead-aptamer-acetamiprid complex. Subsequently, cDNA labeled with fluorescent quantum dots is added, and the nucleic acid aptamer that has bound to acetamiprid cannot bind to the cDNA. At this time, a magnet is used to remove the magnetic beads, and the supernatant is subjected to fluorescence spectroscopy to achieve the detection of acetamiprid.
2. The method according to claim 1, characterized in that: The specific steps include: (1) Preparation of fluorescent quantum dot-labeled cDNA complex: Take 50 μL of 100 nM cDNA modified with biotin and 50 μL of 100 nM fluorescent quantum dot QD solution modified with streptavidin and place them in a centrifuge tube. Incubate at 25°C for 1 h to obtain a complex fluorescent quantum dot-labeled cDNA complex QD-cDNA. (2) Preparation of magnetic bead-aptamer complex: Wash the streptavidin-modified magnetic beads MBs three times with 200 μL of WB buffer at pH 7.5, and resuspend them in 100 μL of 10 mM PBST buffer at pH 7.4 to make the final concentration of the magnetic beads 150 μg / mL; then add 50 μL of 1 μM biotin-modified acetamiprid-specific aptamer Apt, vortex for 30 s, and incubate at 25°C for 1 h. At this time, the biotin modified on Apt combines with the streptavidin modified on MBs to form a magnetic bead-aptamer MBs-Apt complex. After magnetic separation and removal of the supernatant, add 200 μL of PBS-T buffer, repeat washing three times, remove excess Apt in the supernatant, and resuspend in 100 μL PBST buffer to prepare MBs-Apt solution; (3) Fluorescence detection of acetamiprid: 100 μL of the MBs-Apt solution prepared in step (2) and 20 μL of a certain concentration of acetamiprid solution diluted with pH 7.4 PBS buffer were placed in a centrifuge tube, vortexed for 10 s, incubated at 30°C for 1 h, and then 50 μL of the QD-cDNA complex prepared in step (1) was added, vortexed to mix, and incubated at 25°C for 1 h. MBs were then separated from the supernatant using a magnet, the supernatant was collected, placed in a 96-well black ELISA plate, and the fluorescence intensity of the supernatant was detected using a multifunctional ELISA reader.
3. The fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads according to claim 2, characterized in that: The nucleotide sequence of the cDNA in step (1) is: 5'-Biotin-TCTTCATAATATGGTGTCAG-3'.
4. The fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads according to claim 2, characterized in that: The nucleotide sequence of the acetamiprid-specific aptamer Apt in step (2) is: 5'-Biotin-CTGACACCATATTATGAAGA-3'.
5. The fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads according to claim 2, characterized in that: The concentration of the acetamiprid solution in step (3) is 20 to 55 μg / mL.
6. Application of the fluorescence method for on-site detection of acetamiprid based on nanomagnetic beads as claimed in claim 1 in the detection of acetamiprid.
Citation Information
Patent Citations
Method for quantitatively detecting beta-lactoglobulin in milk powder
CN107607722A
Fluorescence detection method for acetamiprid
CN108120704A
Method for detecting content of bisphenol A by electrochemical luminescent adaptor sensor
CN109521073A
Biosensor for detecting salmonella typhimurium and application of biosensor
CN111638330A
High-sensitivity fluorescent adaptive sensor probe based on target induced chain displacement and preparation method thereof
CN118638902A
